Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Lbp Am Sa

LBP AM SA lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 205,305 shares of the biopharmaceutical company's stock after selling 7,530 shares during the period. LBP AM SA's holdings in Gilead Sciences were worth $23,004,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Norges Bank bought a new position in Gilead Sciences in the fourth quarter valued at about $1,789,254,000. FMR LLC lifted its stake in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after buying an additional 7,157,113 shares during the period. GAMMA Investing LLC grew its holdings in Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock worth $285,761,000 after purchasing an additional 2,532,070 shares during the period. Northern Trust Corp raised its stake in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the period. Finally, Royal Bank of Canada grew its position in Gilead Sciences by 30.1% in the 4th quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock valued at $801,655,000 after purchasing an additional 2,005,863 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the subject of several recent analyst reports. Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Morgan Stanley raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Nine equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus price target of $111.38.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the sale, the chief financial officer owned 165,110 shares in the company, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider owned 121,152 shares of the company's stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,500 shares of company stock valued at $6,340,745. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Down 4.3%

Shares of GILD traded down $4.90 during trading hours on Friday, hitting $109.64. The company had a trading volume of 6,115,020 shares, compared to its average volume of 7,700,135. The stock has a market capitalization of $136.38 billion, a price-to-earnings ratio of 23.08, a P/E/G ratio of 0.73 and a beta of 0.29. Gilead Sciences, Inc. has a 52-week low of $68.14 and a 52-week high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The firm has a fifty day moving average price of $107.62 and a 200-day moving average price of $104.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the company earned ($1.32) EPS. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.88%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.